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Chondrosarcoma, the second most frequent primary malignant bone tumor, is classified into three 
grades according to histologic criteria of malignancy. However, a low-grade lesion can be difficult to 
distinguish from a benign enchondroma, while some histologically low-grade lesions may carry a 
poor prognosis. We quantified the receptor for advanced glycation end-products (RAGE) and its 
ligand, high-mobility group box (HMGB) 1 in enchondromas and chondrosarcomas, to determine 
whether these markers were associated with histological malignancy and prognosis.  
METHODS. 
Enchondromas (n=20) and typical chondrosarcomas (n=39) were evaluated for RAGE, endogenous 
secretory RAGE (esRAGE, a splice variant form), and HMGB1 protein expression by 
immunohistochemistry including laser confocal microscopy. Content of esRAGE in resected 
specimens was measured with an enzyme-linked immunosorvent assay. Associations of these 
molecules with histology and clinical behavior of tumors were analyzed. 
RESULTS. 
Expression of esRAGE and HMGB1 was observed in all specimens. Numbers of cells positive for 
esRAGE and HMGB1 expression were positively associated with histologic grade. Expression of 
esRAGE was significantly higher in chondrosarcomas than in enchondromas (P < .001). Tissue 
esRAGE content also was significantly higher in grade 1 and 2 chondrosarcomas than enchondromas 
(P = .0255 and P = .008, respectively). High expression of esRAGE in grade 1 chondrosarcoma was 
associated with subsequent recurrence (P = .0013), lung metastasis (P = .0071), and poor survival (P 
< .001).  
CONCLUSIONS. 
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Chondrosarcomas are the second most frequent primary tumor of bone.1-4 On the basis of 
histologic features, typical chondrosarcomas are divided into grade 1 to 3,3, 5, 6 a distinction long 
considered to correlate with clinical behavior.3, 7 However, distinguishing a low-grade 
chondrosarcoma from a benign enchondroma solely from microscopic cytologic features often is 
impossible.8, 9 Grade 1 chondrosarcomas tend toward slow growth, infrequent metastasis, and an 
overall favorable prognosis. However, since an occasional histologically low-grade tumor shows  
metastatic potential associated with poor prognosis, new diagnostic and prognostic markers for 
chondrosarcomas are needed. 
     The receptor for advanced glycation end-products (RAGE) is a multiligand receptor which has 
an extracellular region, consisting of one V-type and two C-type immunoglobulin-like domains, a 
transmembrane region, and a short C-terminal intracellular portion.10, 11 The V-domain of RAGE is 
critical for binding of various ligands including advanced glycation end-products (AGE),10-14 S100,15, 
16 β−amyloid,17, 18 Mac-1,19 and high-mobility group box-1 (HMGB1),19-23 which have been 
implicated in diabetic vascular complications, neurodegenerative disorders, proinflammatory 
reactions, and cancer.18 Among these ligands, HMGB1 has been linked with tumor growth, invasion, 
and metastasis through interactions with RAGE20, 24 ; RAGE expression has been examined in 
gastric,25 colorectal,26 prostatic,27, 28 lung,26 and breast26 cancers. 
     Recently, Yonekura et al.29 I dentified a novel splice variant of RAGE - endogeneous secretory 
RAGE (esRAGE), which lacked a transmembrane region and represented a soluble form. This 
variant is considered to act as a modulating factor opposing RAGE-associated conditions mentioned 
above and various diseases including cancers. Immunohistochemistry using domain-specific 
antibodies for RAGE or esRAGE showed esRAGE to be distributed in a wide variety of normal 
human organs and tissues.30 However, examination comparing RAGE to esRAGE expression have 
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 not yet been reported in any type of cancer, including bone tumors.  
     In this study we investigated expression of RAGE and esRAGE as well as HMGB1 in surgical 
specimens of enchondroma and chondrosarcomas. We sought associations between expression of 
these molecules and the clinical behavior of these tumors. 
 
PATIENTS AND METHODS 
Patients 
     Resection sprecimens containing enchondromas of long bones (n=20) and specimens 
including typical chondrosarcomas (n=39, grade 1, 24cases; grade 2, 13; and grade 3, 2). Of 39 
specimens in chondrosaroma, 30 primary tumors and individual 9 recurrent lesions were obtained 
from 30 patients. The data from the recurrent tumors were not used for further clinical outcome 
analyses. Specimens studied were obtained from 50 patients (27 male and 23 female), all treated at 
the Kanazawa University Hospital from 1988 to 2004. Locations of enchondromas and 
chondrosarcomas are shown in Table 1. 
     After histologically establishing the diagnosis, all enchondromas were treated by curettage and 
bone grafting. Chondrosarcomas were treated by en-bloc excision. The study was approved by the 
Ethics Committee for Medical Studies at the Kanazawa University Graduate School of Medical 
Science. Written informed consent was obtained from each subject, or their guardian. 
Immunohistochemistry 
     Specimens used had been fixed in 20% formalin and embedded in paraffin. These were retrieved 
from the surgical pathology files of the Pathology Section of Kanazawa University Hospital, School of 
Medicine, Kanazawa University, Kanazawa, Japan. For each case one representative block of 
formalin-fixed, paraffin-embedded tumor tissue was selected. All specimens were decalcified. We 
found that the decalcification step did not influence the IHC for each of the stains. All sections were cut 
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 at a 4-μm thickness for immunohistochemistry. As a control we used a uninvolved epiphyseal cartilage 
resected for osteosarcoma from a distal femur in an 8-year-old girl, because the epiphyseal 
chondrocytes has the active growth and differentiation potential, and some primary bone tumors such 
as osteosarcoma and chondrosarcoma often occur around the growth plate.  Immunostaining 
procedures included a new microwave technique for antigen retrieval as described previously.31 
Primary antibodies used in this study included a goat polyclonal antibody against the V domain of 
RAGE proteins (Chemicon, Temecula, CA; dilution, 1:800) that recognized both full-length and 
esRAGE; a rabbit polyclonal antibody against the C-terminal 16 amino acids of esRAGE (dilution, 
1:1000), recognizing only esRAGE; a rabbit polyclonal antibody against 20 C-terminal amino acids of 
RAGE representing the intracellular domain (Santa Cruz Biotech, Santa Cruz, CA; dilution, 1:100), 
which recognizing the full-length RAGE29; and goat polyclonal antibody against HMGB1 (Santa Cruz 
Biotech.; dilution, 1:50). Peroxidase-labeled polymers of antibodies raised against rabbit polyclonal 
antibody (EnVision, DAKO, Carpinteria, CA) or goat polyclonal antibody (Histone, Simple Stain., 
Nichirei, Tokyo, Japan) were used as a secondary antibody. After visualization of reaction product,, 
sections were counterstained with Meyer’s hematoxylin and then coverslipped for microscopic 
observation. Areas with apparent brown staining were evaluated for positive immunostaining based on 
the manufacturer’s instructions (Envision System, DAKO). In each case, all of positive and negative 
cells were counted in 5 non-overlapping visual fields at ×200 magnification. Labeling index (LI) for 
esRAGE and HMGB1 were calculated as a percentage of positive cells among the total number of 
cells counted at least 250 tumor cells.32
ELISA for esRAGE 
     We examined frozen tissue samples from 10 cases of enchondroma and 11 cases of 
chondrosarcoma (5 grade 1 cases, 6 grade 2 cases) from among the cases used for 
immunohistochemistry. Tissue samples were dissected and homogenized in a lysis buffer (1% 
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 Nonidet P-40, 0.5% deoxycholate, 10 mM EDTA, 0.1% Sodium Dodecyl Sulfate, and 1.0 mM 
Phenylmethylsulfonyl Fluoride) also containing a protease inhibitor cocktail (Sigma-Aldrich, St. 
Louis, MI). The homogenate then was cleared of debris by centrifugation at 12,000 rpm for 30 min at 
4°C. The supernatant was collected, and its total protein concentration was determined (BCA assay 
kit, Model 550, BioRad Laboratories, Hercules, CA). Consentrations pf esRAGE protein were 
determined using a human esRAGE enzyme-linked immunosorbent assay (ELISA) system 
(B-Bridge international, Sunnyvale, CA).33 Twenty micrograms of protein (100 μl of homogenate) 
were used for this assay.. Content of esRAGE protein in tumor tissue is reported as picograms per 
gram of protein.  
Confocal Microscopy 
     The procedure for tissue section treatment was the same as for immunohistochemistry. Primary 
antibodies used included goat polyclonal antibody against the V domain of RAGE (dilution, 1:800); 
rabbit polyclonal antibody specific for esRAGE (dilution, 1:1000); and goat polyclonal antibody 
against HMGB1 (dilution, 1:50). Secondary antibodies were chicken anti-rabbit IgG labeled with 
Alexa Fluor 488 (A-21441, Molecular Probes, Eugene, OR; dilution, 1:200) for esRAGE and 
donkey anti-goat IgG labeled with Alexa Fluor 556 (A-11056, Molecular Probes; dilution, 1:200) for 
the V domain of RAGE and HMGB1. A zeiss confocal microscope (objective lens power, x 63) and 
Bio-Rad 1024 software (Hercules, CA) were used to produce images. 
Statistical Analysis 
     Analyses were performed using Stat View (Version 5.0; SAS Institute, Cary, NC). LI of 
esRAGE and HMGB1 obtained by immunostaining and concentrations of esRAGE protein 
according to ELISA were compared with histologic tumor grades of enchondroma and 
chondrosarcomas by Fisher’s exact test. Correlations between the two variables (esRAGE LI and 
HMGB1 LI) were analyzed using the Pearson correlation coefficient. Associations esRAGE and 
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 HMGB1 LI with subsequent tumor recurrence and distant metastasis were analyzed by Fisher’s exact 
test. Univariate analysis of time to death as a result of chondrosarcomas was carried out using a 




Immunohistochemistry for RAGE, esRAGE, and HMGB1 
     We detected expression of esRAGE (Fig. 1a to e) and HMGB1 (Fig. 1f to j) in all specimens 
examined in this study, including normal epiphyseal cartilage, enchondroma, and chondrosarcoma. In 
an epiphyseal cartilage, the expressions of esRAGE and HMGB1 were observed in the chondrocytes 
from the proliferating through the hypertrophic zones to the calcifying zone, but very weak signals in 
the resting zone. Contrary to our expectation, reaction product staining intensity was very weak in 
enchondroma and chondrosarcoma when specimens were stained with antibody against the 
intracellular domain of RAGE (data not shown). Confocal microscopic distribution of the goat 
polyclonal antibody against the V domain of RAGE proteins, which recognized both RAGE and 
esRAGE proteins, was compared with distribution of the esRAGE-specific antibody, indicating that 
total RAGE signals overlapped with esRAGE signals (Fig. 2a-c). A diffuse cytoplasmic esRAGE 
staining pattern was observed in all tumor cells, but strong staining occupying the entire cytoplasm was 
present only in chondrosarcomas. The esRAGE LI owas 15.7% in normal epiphyseal cartilage 
(control), 33.5 ± 11.4% in enchondroma, 67.7 ± 12.1% in grade 1 chondrosarcoma, 79.0 ± 7.7% in 
grade 2, and 93.6 ± 2.2% in grade 3 (mean ± SD; Fig. 1k). The esRAGE LI was found to increase as 
tumor grade advanced. Significant differences in esRAGE LI were seen not only between grade 1 
chondrosarcomas and enchondromas (P < .0001) but also between in grade 1 and grade 2 
chondrosarcomas (P = .0039; Fig. 1k). Faint cytoplasmic staining for esRAGE was encountered in 
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 scattered chondrocytes of the normal control cartilage.  
     HMGB1 LI was 6.0% in normal epiphyseal cartilage, 42.2 ± 19.0% in enchondroma, 61.8 ± 
19.5% in grade 1 chondrosarcoma, 75.9 ± 11.1% in grade 2 and 77.9 ± 7.7% in grade 3 (mean ± SD; 
Fig. 1l). HMGB1 LI also was found to increase as tumor grade advanced;. HMGB1 LI was 
significantly higher in grade 1 chondrosarcoma than in enchondroma (P = .0006), and a significant 
difference in HMGB1 LI was noted between grade 1 and grade 2 chondrosarcomas (P = .024; Fig. 
1l). A significant positive correlation was found between HMGB1 and esRAGE expression in 
enchondromas and chondrosarcomas (y = 0.532x + 27.283, r = 0.547, P < .0001; Figure 1m).  
     HMGB1-positive cells also were stained by esRAGE-specific antibody. In contrast, signals for 
esRAGE and HMGB1 were not colocalized in chondrosarcoma cells examined by confocal 
microscopy (Fig. 2d-f). A cultured chondrosarcoma cell line H-EMC-SS showed diffuse cytoplasmic 
staining by esRAGE- and HMGB1- specific antibody, but these signals did not necessarily merge 
(data not shown).  
Quantitative Evaluation of esRAGE Protein by ELISA 
     To quantitatively evaluate the esRAGE expression in surgical specimens, an esRAGE ELISA 
was performed in extracts from enchondroma (n=10), and from grade 1 (n=5) and grade 2 (n=6) 
chondrosarcomas. Concentrations of esRAGE protein in enchondroma were significantly lower than 
in grade 1 or grade 2 chondrosarcomas (P = .0255 and P = .008, respectively) (Fig. 3). These findings 
support observations made by esRAGE immunostaining. 
Correlation between esRAGE Expression and Clinical Outcome of Chondrosarcomas 
     A significant association was present between esRAGE LI and subsequent tumor recurrence in 
grade 1 chondrosarcoma (P = .0013; Fig. 4a). Mean esRAGE LI in chondrosarcomas with metastasis 
was significantly higher than in those without metastasis (P = .0071; Fig. 4d); this difference was 
most evident for grade 1 chondrosarcomas (P = .0033; Fig. 4c). A significant difference in survival 
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 time was evident between high (  70%) and low (< 70%) esRAGE LI in patients with 
chondrosarcomas (P = .0017; Fig. 5a). HMGB1 LI was not significantly associated with clinical 




RAGE has been associated with prognosis in several types of cancers such as those of lung,26 
breast,26 and prostate27, 28 as well as melanoma.26 However, RAGE expression and its clinical 
importance in bone tumors had not yet been analyzed. In this study, we selectively detected protein 
expression of esRAGE and RAGE as well the expression of their ligand, HMGB1, in human 
enchondroma and chondrosarcoma specimens. Recently esRAGE has been identified as a novel 
splice variant of RAGE mRNA coding for a soluble form of RAGE.29 Considered a modulating 
factor in cancer phenotypes, esRAGE can trap ligands outside of cells without initiating signal 
transduction within cells. When Cheng, et al.30 performed a systemic analysis of esRAGE expression 
in various human tissues and organs, esRAGE expressions showed patterns distinctive for individual 
organs including brain, thyroid, salivary gland, lung, pancreas, and others. We hypothesized that a 
balance between RAGE and esRAGE expression might be a factor modifying RAGE-associated 
malignant phenotypes.  
Relative expression of esRAGE in chondrosarcoma was associated with histologic grade, 
recurrence, lung metastasis, and clinical outcome; yet RAGE expression was very weak in both 
enchondromas and chondrosarcomas. Confocal microscopic analysis comparing reactive to a 
pan-RAGE antibody and to an esRAGE-specific antibody indicated that the form of RAGE 
predominantly expressed in bone tumors was esRAGE as opposed to membrane-bound RAGE in 
bone tumors. Relative expression of HMGB1 in chondrosarcomas was associated with histologic 
grade but not with lung metastasis or clinical outcome. Colocalization of esRAGE and HMGB1 was 
 10
 not seen,  suggesting that their actions were distinct and that esRAGE could not take part in 
ligand-initiated signal transduction. Mechanisms causing esRAGE and HMGB1 up-regulation in 
chondrosarcoma remain to be investigated.  
    We next focused on esRAGE expression as a diagnostic marker and as a predictor of clinical 
features including prognosis. Histopathologically, chondrosarcomas are divided into three grades 
based on cellularity, atypia, and pleomorphism.3-5 The multiple subtypes of chondrosarcoma based on 
histologic grades have been considered predictive of clinical outcome.3, 7, 34, 35 However, difficulty 
often is encountered even in distinguishing, a low-grade chondrosarcoma from an enchondroma.8, 9 
on the other hand, even though, grade 1 chondrosarcomas have been considered to have a favorable 
prognosis, occasional grade 1 lesions develop metastases resulting in a poor survival outcome. 
Accordingly, many markers and tests have been examined for ability to distinguish low-grade 
chondrosarcoma from enchondroma and to predict clinical outcome in chondrosarcoma. Methods 
have involved DNA content,36, 37 molecular markers (MIB-1,38, 39 p53,40 or hTERT41), cytogenetics,42 
and morphometry.43 Previously, Tsuchiya et al.44 reported histological and clinical findings in six 
cases of borderline chondrosarcoma in which they examined expression of type I, II, III, V, and VI  
collagen, immunohistochemically. Absence of tumor lobule rims containing collagen types I and V 
was useful in distinguishing borderline chondrosarcoma from enchondroma. In our present study, 
two grade 1 chondrosarcomas (in the radius of a 58-year-old man, case 1; in the femur of a 
25-year-old woman, case2) appeared to be borderline chondrosarcomas. LIs for esRAGE and 
HMGB1 representively were 58.2% and 61.5% in case 1 and 64.1% and 69.8% in case 2. The 
patients were treated by curettage and bone grafting based on a frozen-section diagnosis of 
enchondroma. Fortunately no recurrence or metastasis occurred subsequently in either case. Further 
investigation is required concerning expression of esRAGE in very low-grade chondrosarcomas such 
as borderline44 or grade 1/2 lesions.45 Distinguishing an enchondroma from low-grade 
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 chondrosarcoma is among the most important aspects of diagnosis of chondrosarcoma, both for 
planning the surgical procedure and for predicting outcome. 
In this study, esRAGE protein was detected in enchondroma and chondrosarcoma by 
immunohistochemistry and ELISA. The esRAGE LI rose as the histologic grade of the 
chondrosarcoma advanced. A few esRAGE-immunopositive cells were observed in normal 
epiphyseal cartilage used as a control. Staining patterns of esRAGE included a punctuate paranuclear 
pattern and diffuse cytoplasmic staining. Various intensities of diffuse cytoplasmic staining were 
observed in enchondroma and chondrosarcoma cells. Strong staining occupying the entire cytoplasm 
area was detected only in chondrosarcomas. Accordingly, esRAGE LI should be a useful marker for 
distinguishing low-grade from high-grade tumors. Further, esRAGE LI correlated with tumor 
recurrence and lung metastasis in grade 1 chondrosarcomas (P=.0013 and .0033). Generally, grade 1 
chondrosarcoma is considered to grow slowly, metastasize infrequently, and carry a favorable 
prognosis.8 However, in our series 4 of the 17 patients with grade 1 chondrosarcoma developed lung 
metastasis (25%), underscoring that even when the histological diagnosis is grade 1, a few cases 
might have potential for progression. All 4 of these cases showed an esRAGE LI of at least 70%. 
Analysis of cumulative survival rates based on esRAGE LI demonstrated that patients with a high 
esRAGE of at least 70% may have a poor prognosis. Although further studies are required to 
understand the functional roles of esRAGE and mechanisms of its induction in chondrosarcoma, 
esRAGE expression appears to be a promising marker in predicting clinical outcome. 
     In conclusion, we first found that esRAGE indeed was expressed in tumors of cartilage, and 
that relative expression of this protein was associated with histologic tumor grade and cumulative 
survival rate. The esRAGE labeling index could be a useful complement to routine histologic grading 
as a predictor of lung metastasis and survival outcome. Our data therefore supported esRAGE as a 
novel diagnostic and prognostic marker in chondrosarcoma. Further large-scale prospective studies 
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 are warranted to further validate this marker as a routine diagnostic and prognostic tool in assessment 
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 FIGURE LEGENDS 
Fig. 1. Immunohistochemistry for esRAGE (a to e) and HMGB1 (f to j). (a) and (f), normal 
epiphyseal cartilage; (b) and (g), enchondroma; (c) and (h), grade 1 chondrosarcoma; (d) and (i), 
grade 2 chondrosarcoma; (e) and (j), grade 3 chondrosarcoma. (k), esRAGE labeling index and 
histologic tumor grade. (l), HMGB1 labeling index and histologic tumor grade. (EN, enchondroma). 
(m), correlation between HMGB1 and esRAGE in enchondroma and chondrosarcoma 
(y=0.532x+27.283; r=0.547; P<.0001).  
 
Fig. 2. Confocal microscopy. Total RAGE signal [red, (a)] and esRAGE signal [green, (b)] were 
colocalized in a chondrosarcoma specimen [(c), merged image]. Signals for HMGB1 [red, (d)] and 
esRAGE [green, (e)] were not colocalized in chondrosarcoma cells [(f), merged image].  
 
Fig. 3. Quantitative evaluation of esRAGE protein in surgical specimens using an ELISA. 
Concentrations of esRAGE protein in enchondroma were significantly lower than in grade 1 or grade 
2 chondrosarcomas (P = .0255 and P = .008, respectively). 
 
Fig. 4. LI for esRAGE and HMGB1 in patients with chondrosarcoma showing tumor recurrence [(a), 
all grades; (b), grade 1] and lung metastasis [(c), all grades; (d), grade 1]. A significant association 
was present between esRAGE LI and subsequent tumor recurrence in grade 1 chondrosarcoma [P 
= .0013; (a)]. Mean esRAGE LI in chondrosarcomas with metastasis was significantly higher than in 
those without metastasis [P = .0071; (d)]; this difference was most evident for grade 1 
chondrosarcomas [P = .0033; (c)]. 
 
Fig.5. Overall survival in patients with all grades of chondrosarcoma according to (a) esRAGE and 
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 (b) HMGB1. A significant difference in survival time was evident between high (  70%, a dotted 
line and filled square) and low (< 70%, a solid line and filled circles) esRAGE LI in patients with 





Table 1. Patient characteristics 
 enchondroma chondrosarcoma 








  １ 24
  ２ 13
  ３ 2
Location 
humerus 7 4
forearm 1 1
femur 9 6
tibia 3 1
spine 0 4
scapula 0 2
rib 0 1
hand 0 2
pelvis 0 8
sternum 0 1
 




